



Vectored Vaccines

Guest Editors:

Prof. Dr. Amine A. Kamen

Department of Bioengineering,
McGill University, Montreal, QC
H2X 1Y4, Canada

Prof. Dr. Olivier Henry

Department of Chemical
Engineering, Polytechnique
Montréal, Montréal, QC, Canada

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editors

Dear Colleagues,

Vectored vaccines reached important milestones in term of safety and efficacy over the last decade. With the FDA approval in December 2019 of Erbevo, a recombinant Vesicular Stomatitis Virus-Vectored vaccine against Zaire Ebola Virus infection and China FDA approval in October 2017 of an Adenovirus-vectored Ebola vaccine established the regulatory baselines of two important recombinant vaccination platforms.

This special issue will focus on bringing forward the most advanced research and development work on vectored vaccines from antigen design, immunogenicity, protection, manufacturing and delivery. Articles bringing novel perspectives on this broad topic are also welcome including recombinant viral vectors developed as immunotherapeutics or therapeutic vaccines.

Prof. Dr. Amine A. Kamen

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)